Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 81 to 90 of 93 total matches.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
after the final vaccine dose.
Medications that probably do not require timing
adjustments for COVID-19 ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Belimumab (Benlysta) for Lupus Nephritis (online only)
The Medical Letter on Drugs and Therapeutics • Sep 23, 2021 (Issue 1634)
with belimumab.
COVID-19 vaccines can be given without regard to
belimumab treatment.
DOSAGE, ADMINISTRATION ...
The B-lymphocyte stimulator (BLyS)-specific inhibitor
belimumab (Benlysta – GSK), which was approved
earlier for treatment of active, autoantibody-positive,
nonrenal, systemic lupus erythematosus (SLE), has
now been approved for use in addition to standard
therapy for treatment of active lupus nephritis in
adults. Belimumab is the first drug to be approved in
the US for treatment of both SLE and lupus nephritis.
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
after a
pause for the COVID-19 pandemic; the results for all
participants (n=3012) were consistent ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
be considered.
Vaccination of persons with moderate or severe
COVID-19 should be postponed until after ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 doi:10.58347/tml.2023.1687a | Show Introduction Hide Introduction
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
receptor modulators could increase the risk of COVID-19 or its immunological complications is unclear ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
infections, including COVID-19 pneumonia; patients
with an active infection should not receive the drug ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal
Fc receptor (FcRn) blocker, has been approved by the
FDA for treatment of generalized myasthenia gravis in
adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
It is the first drug to be approved for treatment of
generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the
FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart
Hytrulo) and the complement inhibitors eculizumab
(Soliris), ravulizumab (Ultomiris), and zilucoplan
(Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31 doi:10.58347/tml.2024.1696c | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
. Whether
S1P modulators could increase the risk of COVID-19 or
its immunological complications is unclear ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
between October and April, peaking in December or
January. The COVID-19 pandemic disrupted RSV ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
cryptococcal
meningitis have occurred. Whether S1P receptor
modulators could increase the risk of COVID-19 ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.